
News|Articles|December 1, 2001
Bioterror response to alter pharmaceutical development and marketing
Uncle Sam is poised to authorize more than $1 billion to buy medicines and vaccines for the national pharmaceutical stockpile, and federal agencies are gearing up to spend millions more on research related to infectious disease. In response, the pharmaceutical industry is assessing how these developments may alter the way it does business.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Myqorzo is now available for rare heart condition at a $108,400 annual price
2
Medicaid tech companies pledge $600 million to help states update systems
3
FAQ: The uncertain future of enhanced ACA premium subsidies and what it means for U.S. healthcare
4
Why the great pharma-MedTech divide is healthcare’s biggest miss
5























